MAIA MAIA Biotechnology, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1878313 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.4%
TTM EPS YoY36.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-341.5%
ROA-148.3%
ROIC (approx.)-296.5%
Asset turnover—
Leverage & solvency
Liabilities / assets33.6%
Debt / equity0.00x
Current ratio3.41x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| R&D expense | $453,745 | $10.01M |
| SG&A expense | $9.72M | $6.95M |
| Operating income | -$24.27M | -$16.96M |
| Interest expense | — | $57 |
| Pretax income | -$22.39M | -$23.25M |
| Income tax | $2,000 | $2,000 |
| Net income | -$22.40M | -$23.25M |
| EPS (basic) | -0.70 | -1.05 |
| EPS (diluted) | -0.70 | -1.05 |
| Weighted avg. shares (diluted) | 32.11M | 22.20M |
| Balance sheet | ||
| Cash & equivalents | $0 | $0 |
| Current assets | $9.70M | $10.15M |
| Total assets | $9.70M | $10.16M |
| Current liabilities | $5.84M | $3.83M |
| Total liabilities | $7.33M | $6.52M |
| Shareholders' equity | $2.38M | $3.63M |
| Shares outstanding | 38.62M | 26.16M |
| Cash flow statement | ||
| Operating cash flow | -$18.84M | -$15.70M |
| Financing cash flow | $17.91M | $18.18M |
| Stock-based compensation | $2.63M | $1.91M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.